Oral cyclophosphamide in recurrent ovarian cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 12, Issue 1, 2016, Pages e154-e160

  Handolias, Despina ^a,b   Quinn, Michael ^a,c   Foo, Serene ^d   Mileshkin, Linda ^b,c,d   Grant, Peter ^c,d   Dutu, Gaelle ^b   Rischin, Danny ^b,c,d  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MERCY HOSPITAL FOR WOMEN   (Australia)

Author keywords

Cancer; Cyclophosphamide; Ovarian; Platinum; Recurrence

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM COMPLEX; TOPOTECAN; ALKYLATING AGENT;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; AUSTRALIA; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; HUMAN; HYPERSENSITIVITY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; FEMALE; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORAL DRUG ADMINISTRATION; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; AUSTRALIA; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84973577739     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12074     Document Type: Article

References (30)

1. Aabo K, Adams M, Adnitt P etal. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78: 1479-1487.
2. Markman M, Rothman R, Hakes T etal. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
3. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol 1997; 65: 434-436.
4. Navo M, Kunthur A, Badell ML etal. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006; 103: 608-613.
5. Morgan JS, Adams M, Mason MD. Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 1994; 30A: 1205-1206.
6. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15: 13-18.
7. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53: 121-122.
8. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7 (Suppl 5): 20-28.
9. Decker DG, Mussey E, Malkasian GD Jr, Johnson CE. Cyclophosphamide in the treatment of ovarian cancer. Clin Obstet Gynecol 1968; 11: 382-400.
10. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 1998; 352: 1571-1576.
11. McGuire WP, Hoskins WJ, Brady MF etal. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
12. Piccart MJ, Bertelsen K, James K etal. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699-708.
13. Garcia AA, Hirte H, Fleming G etal. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26: 76-82.
14. Sanchez-Munoz A, Mendiola C, Perez-Ruiz E etal. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology 2010; 79: 98-104.
15. Donawho CK, Luo Y, Penning TD etal. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-2737.
16. Dent R, Linderman GJ, Clemons M, etal. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010; 28: 15s (suppl; abstr 1-18).
17. Giaccone G, Rajan A, Kelly RJ etal. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. J Clin Oncol 2012; 28: 15S (suppl; abstr 3027).
18. Ji JJ, Kummar S, Chen AP etal. Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas. J Clin Oncol 2010; 28: 1s (suppl; abstr 2514).
19. Kummar S, Ji J, Morgan R etal. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012; 18: 1726-1734.
20. Rustin GJ, Quinn M, Thigpen T etal. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004; 96: 487-488.
21. Watanabe Y, Etoh T, Koike E, Mizuno Y, Wang, WM, Hoshiai, H. Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer. Int J Clin Oncol 2010; 15: 468-471.
22. Samaritani R, Corrado G, Vizza E, Sbiroli C. Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer 2007; 7: 65.
23. Cheng X, Moroney JW, Levenback CF, Fu S, Jaishuen A, Kavanagh JJ. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother 2009; 21: 566-572.
24. Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007; 107: 326-330.
25. Sanchez-Munoz A, Jurado JM, Perez-Ruiz E, Alba E. Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer. Clin Transl Oncol 2009; 11: 329-331.
26. Matulonis UA, Pereira L, Liu J etal. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol 2012; 126: 41-46.
27. Konstantinopoulos PA, Spentzos D, Karlan BY etal. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010; 28: 3555-3561.
28. Yang D, Khan S, Sun Y etal. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306: 1557-1565.
29. Osher DJ, Kushner YB, Arseneau J, Foulkes WD. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? J Clin Pathol 2011; 64: 924-926.
30. Kummar S, Oza AM, Fleing GF etal. Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. J Clin Oncol 2012; 30 (suppl; abstr 5020).